China AI-driven drug discovery (AIDD) Report Interpretation

Overview

This China AIDD earnings review assesses the sector's shift from standalone AI platforms toward integrated ecosystems combining technology, capital, partnerships and proprietary assets. HSBC views Insilico as the preferred exposure because its commercial traction and clinical progress support its “IP factory” model, while XtalPi remains a Hold as its proprietary-pipeline transition requires proof.

Core views

HSBC argues that 1H26 broadly validated monetisation across its China AIDD coverage, although much of the upside is longer dated. Insilico's revenue rose 287% year on year to USD106.3m, broadly matching HSBC's USD104.9m estimate, and it generated USD35.5m of net profit, about 12% above estimate on stronger margins. XtalPi's reported revenue declined 24% year on year to RMB393.6m and was about 33% below estimate, primarily because its RMB129.4m DoveTree second milestone was recognised later than expected; excluding the high-base USD51m DoveTree upfront payment in 1H25, revenue grew 74%, while AI4S revenue rose 136%. The two stocks' performance had diverged sharply, with Insilico up about 40% year to date and XtalPi down about 28%, versus the HSI down 3%. The report sees three structural changes reshaping AIDD: platforms are becoming integrated ecosystem fund-plus-platform businesses; commercialisation is increasingly based on both BD and owned assets, with expansion into peptides, pain, ophthalmology and longevity; and the technology architecture is moving from expert GUI tools toward multimodal, agentic AI workflows measured by real-world productivity benchmarks. In HSBC's view, repeatable BD is the clearest near-term catalyst. For Insilico, it forecasts 2026 revenue of USD187m, including USD113.7m from BD and USD60.8m from CRO, expects profit breakeven in 2027e, and expects gross margin to remain structurally high at 85-90% because of the upfront- and milestone-payment mix. Insilico is HSBC's preferred stock because the institution views its business model as a scalable “IP factory.” Its 1H26 growth was supported by multiple drug-discovery collaborations, the NLRP3 first-dose milestone from Hygtia, software-solutions revenue growth of 34% year on year, and a major licensing-out transaction with Eli Lilly. The company also raised USD305m through a zero-coupon convertible bond due in 2027, with an initial conversion price of HKD58.07, a 15.0% premium to the 11 September 2026 closing price. HSBC believes BD breadth, cash and external pharma validation partly buffer single-asset risk. The central clinical catalyst is rentosertib, for which the first patient was dosed on 10 September 2026 in the 52-week, 320-participant Phase III GENESIS-IPF-3 study across 47 China sites. Its primary endpoint is the annual rate of forced vital capacity decline over 52 weeks. HSBC highlights company-reported Phase II evidence suggesting biological-age reversal: longitudinal Olink data covering 2,841 proteins from 42 participants were assessed using six machine-learning proteomic aging clocks and benchmarked against 55,319 UK Biobank profiles. The models indicated lower predicted biological age versus placebo, with several implying a three-to-four-year reversal and one up to six years. HSBC considers this incrementally bullish because it strengthens platform credibility and long-term indication optionality, but does not include a longevity indication in valuation or change its 2026-28 earnings forecasts. HSBC values Insilico using SOTP. Its software-solutions segment is valued at 16x EV/revenue for implied EV of USD118m; the internal pipeline, CRO and BD segment uses risk-adjusted NPV and is valued at USD4.2bn, down from USD4.4bn; and the AI discovery platform is valued as an asset factory at USD1.2bn. Including USD80m for other discovery, implied EV is USD5.6bn, down from USD5.8bn. The assumptions include 9.6% WACC, 3.0% terminal growth and end-2026 USD/HKD of 7.83. The higher cash balance after the convertible offering lifts the target price to HKD85.90 from HKD84.50; HSBC maintains Buy and states 65.5% upside. For XtalPi, HSBC acknowledges the computational strength of its platform but is cautious about management's shift from a software/CRO-led model toward a biotech asset generator. Partnered programs provide near-term milestones and preclinical validation while limiting R&D burn, but wholly owned programs are expected to enter IND-enabling stages over the next 12-24 months, materially changing capital needs and risk. HSBC characterises the stock as a “show-me” story and will await concrete clinical data before giving proprietary assets credit in its DCF. Delayed DoveTree revenue recognition led HSBC to cut XtalPi revenue estimates by 2-3% for 2026-28e, with 2026e revenue reduced to RMB988.8m, 2027e to RMB1,364.8m and 2028e to RMB1,825.1m. The institution uses a DCF with 9.9% WACC, 3.0% perpetual growth, a 4.25% risk-free rate, 4.75% mainland H-share equity risk premium, beta of 1.39 and end-2026e RMB/HKD of 1.17. The revised HKD7.70 target price, down from HKD8.00, implies about 13% upside; HSBC maintains Hold because it considers the valuation fair given both near-term opportunities and execution risks.

Analysis framework

HSBC first compares 1H26 financial results with its prior estimates, then assesses commercial BD progress, pipeline and clinical milestones, and the sector's technology and business-model evolution. It values Insilico by separately estimating software, pipeline/CRO/BD and platform value, while it applies a cash-flow-based DCF to XtalPi and withholds proprietary-pipeline credit until clinical evidence emerges.

Methodology notes

• Valuation methodsSOTP (Sum-of-the-Parts) Valuation

  Sum-of-the-parts valuation for Insilico

  HSBC separately values software solutions, the internal pipeline/CRO/BD business, the AI discovery platform and other discovery, then adds the parts to derive enterprise value and the target price.

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation for XtalPi

  HSBC discounts projected free cash flow and terminal value using a 9.9% WACC and 3.0% perpetual growth rate to derive XtalPi's equity value and HKD7.70 target price.

• Valuation methods

  Risk-adjusted NPV for Insilico's internal pipeline, CRO and BD segment

  The approach incorporates clinical probabilities of success, contracted milestones, expected peak sales and a 9.6% WACC to reflect the uncertainty of development-stage assets.

• Other

  Proteomic aging-clock analysis

  The report describes six independent machine-learning models applied to longitudinal protein data and benchmarked against UK Biobank profiles to assess whether rentosertib affected predicted biological age.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Insilico (3696 HK)

  HSBC's preferred AIDD exposure, supported by BD monetisation, platform scalability and rentosertib clinical progress.

  Strengths

  1H26 revenue rose 287% year on year to USD106.3m; net profit turned positive; BD pipeline, cash and external pharma validation support the platform.

  Weaknesses

  The longevity thesis is not yet a primary valuation driver, and much optionality remains longer dated.

  Comparison

  HSBC prefers Insilico to XtalPi because Insilico has nearer-term clinical positioning and a broader deal pipeline.

  Risks

  Clinical failure of key assets, weak deal activity, uncertain milestone timing, technological disruption, competition and geopolitical risk.

• XtalPi (2228 HK)

  Covered AIDD company retained at Hold while HSBC awaits proof of its proprietary-pipeline transition.

  Strengths

  Computational platform strength and partnered programs provide preclinical validation, milestone opportunities and some protection from R&D burn.

  Weaknesses

  1H26 revenue missed expectations because of delayed milestone recognition, and the shift to wholly owned programs increases capital-allocation and execution risk.

  Comparison

  HSBC considers XtalPi a “show-me” story relative to preferred pick Insilico.

  Risks

  Milestone-payment delays, intensifying competition, regulatory and foreign-exchange risk.

Key data

• Insilico 1H26 revenueUSD106.3mUp 287% year on year; 1% above HSBC's USD104.9m estimate.
• Insilico 1H26 net profitUSD35.5mTurned positive and was about 12% above HSBC's prior estimate.
• Insilico target priceHKD85.90Raised from HKD84.50; HSBC states 65.5% implied upside.
• XtalPi 1H26 revenueRMB393.6mDown 24% year on year and about 33% below HSBC's RMB589.1m estimate due to delayed DoveTree milestone recognition.
• XtalPi target priceHKD7.70Lowered from HKD8.00; implies about 13% upside.
• Rentosertib Phase III trialFirst patient dosed 10 September 2026GENESIS-IPF-3 is a 52-week, 320-participant trial with annual FVC decline as the primary endpoint.

Impact & implications

HSBC believes the AIDD investment case is broadening from near-term software and service revenue toward BD repeatability, proprietary assets and agentic-AI-enabled productivity. It sees Insilico's platform-plus-lead-asset model as better supported by current financial, BD and clinical evidence, whereas XtalPi requires evidence that its asset-heavy transition can translate into clinical and financial value.

Risks

• For Insilico: failure in a key clinical trial, weaker-than-expected deal activity, delays in converting platform output into partnerships, unpredictable revenue and milestone timing, technological disruption, intense competition and geopolitical risk.
• For XtalPi: delayed milestone payments, intensifying competition, regulatory risk and foreign-exchange risk.

What to watch

• Insilico's ability to execute repeatable BD transactions and deliver its forecast BD and CRO revenue.
• Rentosertib's Phase III IPF progress and subsequent clinical readouts.
• Evidence that new longevity, anti-aging, pain and ophthalmology opportunities can translate into clinically validated assets.
• XtalPi's recognition of the DoveTree milestone payment and delivery against revised revenue estimates.
• Clinical data from XtalPi's proprietary pipeline as it moves toward IND-enabling and clinical stages.
• Potential XtalPi catalysts including major MNC partnerships, robotics-capacity completion, pipeline-company IPO/M&A and an operating-leverage inflection.